XOMA: Short Perindopril Data May 'Coveram' for NDA Filing
Six weeks of positive results in Phase III trials with the fixed-dose combination (FDC) of perindopril arginine with amlodipine besylate for high blood pressure should be enough – when packaged with data from overseas, where it's marketed already as Coveram – to justify a new drug application (NDA), said XOMA Corp.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter